Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Time to Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Friday. The stock had previously closed at $15.90, but opened at $15.25. Ascentage Pharma Group International shares last traded at $15.2650, with a volume of 1,010 shares traded.

Wall Street Analysts Forecast Growth

AAPG has been the topic of a number of recent research reports. BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target for the company. Finally, Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The company has a fifty day moving average price of $17.09 and a two-hundred day moving average price of $19.64. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million during the quarter. As a group, sell-side analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.